Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from A Distinct Delayed-Onset Intraocular Inflammation Phenotype of Faricimab versus Aflibercept and Ranibizumab: Triangulated Pharmacovigilance Evidence from Databases of US, Europe and Japan. Local targets link to admitted publications; unresolved targets remain external evidence.
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis
10.1016/s2214-109x(13)70145-1 · 2014 · External reference
Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study
10.1016/s2214-109x(20)30489-7 · 2021 · External reference
10.1097/01.iae.0000242842.14624.e7
10.1097/01.iae.0000242842.14624.e7 · External reference
Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration
10.3928/1542-8877-20050701-14 · 2005 · External reference
10.1056/nejmoa054481
10.1056/nejmoa054481 · External reference
10.1016/j.ophtha.2012.09.006
10.1016/j.ophtha.2012.09.006 · External reference
Pharmacological principles of intravitreal drug therapy and their implications for clinical practice: a primer for the ophthalmologist
10.1038/s41433-026-04540-y · 2026 · External reference
Noninfectious Intraocular Inflammation After Intravitreal Aflibercept
10.1001/jamaophthalmol.2025.0969 · 2025 · External reference
Long-term outcomes of intravitreal anti-VEGF therapies in patients affected by neovascular age-related macular degeneration: a real-life study
10.1186/s12886-021-02055-6 · 2021 · External reference
Cardiovascular and Cerebrovascular Adverse Events Associated with Intravitreal Anti-VEGF Monoclonal Antibodies: A World Health Organization Pharmacovigilance Study
10.1016/j.ophtha.2024.07.008 · 2025 · External reference
Inflammation and Occlusive Retinal Vasculitis Post Faricimab
10.1001/jamaophthalmol.2024.5889 · 2025 · External reference
Faricimab: Transforming the Future of Macular Diseases Treatment - A Comprehensive Review of Clinical Studies
10.2147/dddt.s427416 · 2023 · External reference
, Rapid Fluid Resolution and Durability With Faricimab in Neovascular Age-Related Macular Degeneration
10.1001/jamaophthalmol.2025.6365 · 2026 · External reference
Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema
10.1016/j.oret.2025.01.017 · 2025 · External reference
Faricimab: current evidence for the treatment of retinal vein occlusion
10.1007/s00417-026-07304-2 · 2026 · External reference
Severe Intraocular Inflammation After Intravitreal Injection of Faricimab: A Single-Site Case Series of Six Patients
10.1016/j.ajo.2024.08.008 · 2025 · External reference
Severe Intraocular Inflammation Following Intravitreal Faricimab
10.1001/jamaophthalmol.2024.0530 · 2024 · External reference
Safety profile of faricimab: a multi-source pharmacovigilance analysis using FAERS and JADER
10.1186/s40360-025-00902-6 · 2025 · External reference
Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
10.3389/fphar.2025.1521358 · 2025 · External reference
10.1002/pds.4944
10.1002/pds.4944 · External reference
10.1007/s40264-018-0647-1
10.1007/s40264-018-0647-1 · External reference
10.1002/pds.668
10.1002/pds.668 · External reference
10.1002/pds.677
10.1002/pds.677 · External reference
10.1007/s002280050466
10.1007/s002280050466 · External reference
10.1177/0962280211403604
10.1177/0962280211403604 · External reference
10.1007/s40264-013-0061-7
10.1007/s40264-013-0061-7 · External reference
10.1007/s40264-024-01421-9
10.1007/s40264-024-01421-9 · External reference
10.1038/nrd3700
10.1038/nrd3700 · External reference
10.1038/nrd2157
10.1038/nrd2157 · External reference
Faricimab: expanding horizon beyond VEGF
10.1038/s41433-019-0670-1 · 2020 · External reference
Retinal Vasculitis and Intraocular Inflammation after Intravitreal Injection of Brolucizumab
10.1016/j.ophtha.2020.04.017 · 2020 · External reference
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials
10.1016/s0140-6736(22)00018-6 · 2022 · External reference
Ocular inflammation after agitation of siliconized and silicone oil-free syringes: a randomized, double-blind, controlled clinical trial
10.1186/s40942-022-00387-z · 2022 · External reference
Intravitreal ranibizumab for persistent diabetic vitreous haemorrhage: a randomised, double-masked, placebo-controlled feasibility study
2020 · External reference
Systemic Effects of Intravitreal Anti-VEGF Therapy: A Review of Safety across Organ Systems
10.1007/s40123-025-01157-4 · 2025 · External reference
10.1016/j.ophtha.2024.02.014
10.1016/j.ophtha.2024.02.014 · External reference
Bilateral Occlusive Retinal Vasculitis After Faricimab Rechallenge
10.1001/jamaophthalmol.2026.1610 · 2026 · External reference
10.1186/s12348-026-00635-5
10.1186/s12348-026-00635-5 · External reference
